Comparison

Recombinant Human TWEAK Receptor

Item no. CS-CRT601B
Manufacturer Cell Sciences
Amount 25 ug
Category
Type Proteins
Specific against Human (Homo sapiens)
Host E.coli
Purity >95% by SDS-PAGE and HPLC analyses.
Sequence EQAPGTAPCS RGSSWSADLD KCMDCASCRA RPHSDFCLGC AAAPPAPFRL LWP
ECLASS 10.1 32160409
ECLASS 11.0 32160409
UNSPSC 12352202
Similar products CD266, FN14, TWEAKR, type I transmembrane protein Fn14, FGF-inducible 14, tumor necrosis factor receptor superfamily member 12A, tweak-receptor, fibroblast growth factor-inducible immediate-early response protein 14
Available
Manufacturer - Category
Biomolecules
Storage Conditions
This lyophilized preparation is stable at 2-4C, but should be kept desiccated at -20C for long term storage. Upon reconstitution, the preparation is stable for up to one week at 2-4C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20C to -80C. Avoid repeated freeze/thaw cycles.
Molecular Weight
Approximately 5.6 kDa, a single non-glycosylated polypeptide chain containing 53 amino acids.
Description
Human TNF-related weak inducer of apoptosis receptor (TWEAKR) also known as Tumor necrosis factor receptor superfamily member 12A precursor (gene name TNFRSF12A) or fibroblast growth factor-inducable 14 kD protein, is distantly related to the TNFR family, containing one cysteine-rich domain in the extracellular region and a TNFR-associated factor binding domain but does not contain a death domain (DD) cytoplasmic region. It is expressed in the spleen, thymus, peripheral blood lymphocytes, colon, and small intestine. Signal transduction by TWEAKR can be activated by either the membrane anchored or the soluble TWEAK. In addition, It plays a role in TWEAK-induced endothelial cell migration, proliferation, and angiogenesis.
Formulation
Lyophilized from a 0.2 um filtered concentrated solution in PBS, pH 7.4.
Reconstitution
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at <-20C. Further dilutions should be made in appropriate buffered solutions.
Biological Activity
Fully biologically active when compared to standard. The ED50 determined by inhibiting TWEAK dependent proliferation of human uMbilical vein endothelial cells (HUVEC) is less than 30 ng/ml, corresponding to a specific activity of >3.3x104 IU/mg, in the presence of 15 ng/ml of rHuTWEAK.
Endotoxin Level
Less than 1EU/ug of rHuTWEAKR as determined by LAL method.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 25 ug
Available: In stock
available

Delivery expected until 8/7/2025 

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close